Article Listing - Data show Novo Nordisk’s ultra-long-acting insulin degludec can be flexibly dosed
Rising drug resistance driving early-line use of powerful antibiotics, according to surveyed EU5 physicians
13 June 2013
More than half of physicians surveyed by health care advisory firm, Decision Resources from the EU5 (France, Germany, Italy, Spain and the UK) prescribe carbapenems, especially meropenem (Cubist/AstraZeneca's Merrem/Meronem; Dainippon Sumitomo's Meropen; generics) and imipenem/cilastatin (Merck's Primaxin/Tienam; generics), as first- or second-line therapy for Gram-negative infections (GNIs) due to ESBL-producing Enterobacteriaceae.
Generics triple-therapy just as effective as brand-name Enbrel, new study shows
13 June 2013
Global biotech leader Amgen's (Nasdaq: AMGN) branded drug Enbrel (etanercept) is no more effective in treating rheumatoid arthritis than cheaper generic drugs, according to new research published in the Journal of the Medical Association, funded by the US Department of Veteran Affairs.
Teva and Active Biotech to move forward with laquinimod on positive Ph IIa results in active lupus nephritis
13 June 2013
Israel's Teva Pharmaceutical Industries (NYSE: TEVA) and Swedish partner Active Biotech (OMX NORDIC: ACTI) have released positive results of a Phase IIa study of oral laquinimod designed to assess safety, tolerability and clinical efficacy in patients with active lupus nephritis, one of the most serious manifestations of systemic lupus erythematosus (SLE or lupus) that can lead to chronic kidney failure.
Over 200 novel drugs in development for heart disease and stroke, says PhRMA
13 June 2013
America's biopharmaceutical research companies are developing 215 medicines for two of the leading causes of death of Americans - heart disease and stroke, according to a new report and overview released yesterday (June 12) by the Pharmaceutical Research and Manufacturers of America (PhRMA).
NICE final draft guidance on Eli Lilly's Alimta negative
13 June 2013
UK drugs watch dog the National Institute for Health and Care Excellence (NICE) this morning (June 13) issued final draft guidance not recommending US drug major Eli Lilly's Alimta (pemetrexed) for the maintenance treatment of non-small-cell lung cancer (NSCLC) following induction therapy with pemetrexed and cisplatin.
Pfizer in $2.15 billion settlement from Teva and Sun for infringement of Protonix patent
12 June 2013
Global pharma behemoth Pfizer (NYSE: PFE) today (June 12) said it has reached a $2.15 billion settlement reached with Israel-based Teva Pharmaceuticals Industries (NYSE: TEVA) and India's Sun Pharmaceutical Industries (SUNP: IN) for patent-infringement damages resulting from their "at-risk" launches of generic Protonix (pantoprazole) in the USA.
American Diabetes Association calls for independent review of incretin-based therapy
12 June 2013
The American Diabetes Association is asking all pharmaceutical companies involved in the development or marketing of incretin-based medications, used to lower blood glucose levels, to make patient-level data on their products available for an independent review that could help settle the question of whether such therapies contribute to the development of pancreatitis or pancreatic cancer.
Amgen and Cytokinetics expand omecamtiv mecarbil accord
12 June 2013
USA-based Amgen (Nasdaq: AMGN), the world's largest independent biotech company, has expanded its strategic collaboration with Cytokinetics (Nasdaq: CYTK) to include Japan. In 2006, Cytokinetics and Amgen entered into a collaboration to discover, develop and commercialize novel small-molecule therapeutics that activate cardiac muscle contractility for potential applications in the treatment of heart failure.
Therapeutic effects of Eisai's lenvatinib in melanoma confirmed
12 June 2013
Japanese drug major Eisai (TYO: 4523) says that the therapeutic effects of lenvatinib, a VEGF receptor tyrosine kinase inhibitor and multi-kinase inhibitor discovered in-house, on melanoma have been confirmed in one of a series of joint development programs being conducted as part of the company's strategic collaboration with Quintiles (NYSE: Q). The finding has provided the basis for the first proof of concept (POC) to be achieved under the partnership.
Bristol-Myers Orencia equals Humira in head-to-head AMPLE RA study
12 June 2013
US drug major Bristol-Myers Squibb (NYSE: BMY) has announced the results of year two data from AMPLE (Abatacept Versus Adalimumab Comparison in Biologic-Naive rheumatoid arthritis (RA) Subjects With Background Methotrexate), a first-of-its-kind trial of 646 patients comparing the subcutaneous (SC) formulation of Orencia (abatacept) versus AbbVie's (NYSE: ABBV) blockbuster drug Humira (adalimumab), each on a background of MTX, in biologic naive patients with moderate to severe RA. The AMPLE year two data are being presented this week at the European League Against Rheumatism (EULAR) annual congress and highlighted during a congress press conference.
- US Supreme Court says patent settlement can "sometimes" be illegal
- InSite Vision joins Merck & Co and Pfizer in patent infringement law suit against
- Highlights of EHA meeting: Novartis' Jakavi; Bristol-Myers and AbbVie's elotuzumab; Janssen's ibrutinib
- Daiichi Sankyo files for Japanese approval of Prasugrel
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
